Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBCC 2024 | Important biomarkers in luminal type breast cancer and DCIS

Zsuzsanna Varga, MD, University Hospital Zurich, Zurich, Switzerland, discusses the role of molecular analysis in subtypes of breast cancer such as luminal type breast cancer and ductal carcinoma in situ (DCIS). ER, PR and HER2 are commonly assessed in typical cases and immunohistochemistry or FISH tests can identify these proteins. However, issues may arise in luminal A and B breast cancer. Prof. Varga additionally highlights liquid biopsy in the metastatic setting, as well as ESR1 and PI3K mutations. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.